ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
CHARLES OKONKWO M.D.

Cardiovascular Disease

6,422

$566K

142
106 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

54%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 28%

$88
Average prescription price

Avg: $67

ARMEN AGHABEGIAN P.A.

Cardiovascular Disease

253

$5,290

96
78 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

6%
prescriptions for brand name drugs

Avg: 28%

$21
Average prescription price

Avg: $67

WINDGROVE DANIEL M.D

Cardiovascular Disease

2,655

$94K

82
42 are 65+

22%
patients receiving schedule two controlled substances

Avg: 0%

52%
patients receiving schedule three controlled substances

Avg: 2%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$35
Average prescription price

Avg: $67

PAMELA ROHRER NP

Cardiovascular Disease

448

$20.4K

125
108 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

54%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 28%

$45
Average prescription price

Avg: $67

RAIF TAWAKOL MD

Cardiovascular Disease

6,643

$761K

113
61 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

52%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$115
Average prescription price

Avg: $67

ZAKA VERA M.D.

Cardiovascular Disease

2,603

$84.2K

324
172 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

29%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 28%

$32
Average prescription price

Avg: $67

DALE STEMPLE M.D.

Cardiovascular Disease

10,989

$723K

410
270 are 65+

23%
patients receiving schedule two controlled substances

Avg: 0%

34%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$66
Average prescription price

Avg: $67

JIJIBHOY PATEL MD

Cardiovascular Disease

2,175

$189K

52
31 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$87
Average prescription price

Avg: $67

JONATHAN TURNER M.D.

Cardiovascular Disease

281

$11.1K

111
99 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

46%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

11%
prescriptions for brand name drugs

Avg: 28%

$39
Average prescription price

Avg: $67

PRASAD MUMMANENI MD

Cardiovascular Disease

7,501

$448K

189
146 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

26%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 28%

$60
Average prescription price

Avg: $67

SONIA SAWAL M.D.

Cardiovascular Disease

12,256

$508K

463
418 are 65+

8%
patients receiving schedule two controlled substances

Avg: 0%

28%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 28%

$41
Average prescription price

Avg: $67

TING TSAI M.D.

Cardiovascular Disease

877

$49.9K

105
59 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

26%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 28%

$57
Average prescription price

Avg: $67

RAZMIK OHANJANIAN MD

Cardiovascular Disease

43,890

$3.05M

723
667 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

20%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$69
Average prescription price

Avg: $67

JOHN SMITH MD

Cardiovascular Disease

8,693

$605K

275
247 are 65+

9%
patients receiving schedule two controlled substances

Avg: 0%

23%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 28%

$70
Average prescription price

Avg: $67

AARON JORDAN MD

Cardiovascular Disease

16,694

$704K

633
541 are 65+

7%
patients receiving schedule two controlled substances

Avg: 0%

27%
patients receiving schedule three controlled substances

Avg: 2%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 28%

$42
Average prescription price

Avg: $67

T.S.S RAJAN M.D

Cardiovascular Disease

2,238

$74.8K

70
57 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

17%
patients receiving schedule three controlled substances

Avg: 2%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 28%

$33
Average prescription price

Avg: $67

JOSE ROCAMORA MD

Cardiovascular Disease

45,055

$2.14M

1473
1174 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

21%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 28%

$48
Average prescription price

Avg: $67

MICHAEL NORMAN DO

Cardiovascular Disease

21,812

$1.15M

1157
938 are 65+

6%
patients receiving schedule two controlled substances

Avg: 0%

20%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 28%

$53
Average prescription price

Avg: $67

ROLLINGTON FERGUSON MD

Cardiovascular Disease

12,011

$907K

546
325 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

26%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 28%

$75
Average prescription price

Avg: $67

GOPAL GOVINDARAJAN M.D. F.A.C.C.

Cardiovascular Disease

11,538

$700K

344
296 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

19%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 28%

$61
Average prescription price

Avg: $67

VINOD MALHOTRA MD

Cardiovascular Disease

10,188

$531K

478
340 are 65+

9%
patients receiving schedule two controlled substances

Avg: 0%

22%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 28%

$52
Average prescription price

Avg: $67

MIN SHIN MD,APC

Cardiovascular Disease

7,383

$271K

258
220 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

24%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 28%

$37
Average prescription price

Avg: $67

JIHAD AL IMAMI M.D.

Cardiovascular Disease

3,049

$449K

200
185 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 28%

$147
Average prescription price

Avg: $67

DAVID KATTAN M.D.

Cardiovascular Disease

8,511

$572K

387
330 are 65+

4%
patients receiving schedule two controlled substances

Avg: 0%

21%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 28%

$67
Average prescription price

Avg: $67

WILLIAM DAVIS M.D.

Cardiovascular Disease

4,465

$212K

250
128 are 65+

12%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$48
Average prescription price

Avg: $67

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank